BACKGROUND: Patient outcomes following resection of colorectal liver metastases (CLM) after second-line chemotherapy regimen is unknown. METHODS: From August 1998 to June 2009, data from 1099 patients with CLM were collected prospectively. We retrospectively analyzed outcomes of patients who underwent resection of CLM after second-line (2 or more) chemotherapy regimens. RESULTS: Sixty patients underwent resection of CLM after 2 or more chemotherapy regimens. Patients had advanced CLM (mean number of CLM ± standard deviation, 4 ± 3.5; mean maximum size of CLM, 5 ± 3.2 cm) and had received 17 ± 8 cycles of preoperative chemotherapy. In 54 (90%) patients, the switch from the first regimen to another regimen was motivated by tumor progression or suboptimal radiographic response. All patients received irinotecan or oxaliplatin, and the majority (42/60 [70%]) received a monoclonal antibody (bevacizumab or cetuximab) as part of the last preoperative regimen. Postoperative morbidity and mortality rates were 33% and 3%, respectively. At a median follow-up of 32 months, 1-year, 3-year, and 5-year overall survival rates were 83%, 41%, and 22%, respectively. Median chemotherapy-free survival after resection or completion of additional chemotherapy administered after resection was 9 months (95% confidence interval, 4-14 months). Synchronous (vs metachronous) CLM and minor (vs major) pathologic response were independently associated with worse survival. CONCLUSIONS: Resection of CLM after a second-line chemotherapy regimen was found to be safe and was associated with a modest hope for definitive cure. This approach represents a viable option in patients with advanced CLM.
BACKGROUND:Patient outcomes following resection of colorectal liver metastases (CLM) after second-line chemotherapy regimen is unknown. METHODS: From August 1998 to June 2009, data from 1099 patients with CLM were collected prospectively. We retrospectively analyzed outcomes of patients who underwent resection of CLM after second-line (2 or more) chemotherapy regimens. RESULTS: Sixty patients underwent resection of CLM after 2 or more chemotherapy regimens. Patients had advanced CLM (mean number of CLM ± standard deviation, 4 ± 3.5; mean maximum size of CLM, 5 ± 3.2 cm) and had received 17 ± 8 cycles of preoperative chemotherapy. In 54 (90%) patients, the switch from the first regimen to another regimen was motivated by tumor progression or suboptimal radiographic response. All patients received irinotecan or oxaliplatin, and the majority (42/60 [70%]) received a monoclonal antibody (bevacizumab or cetuximab) as part of the last preoperative regimen. Postoperative morbidity and mortality rates were 33% and 3%, respectively. At a median follow-up of 32 months, 1-year, 3-year, and 5-year overall survival rates were 83%, 41%, and 22%, respectively. Median chemotherapy-free survival after resection or completion of additional chemotherapy administered after resection was 9 months (95% confidence interval, 4-14 months). Synchronous (vs metachronous) CLM and minor (vs major) pathologic response were independently associated with worse survival. CONCLUSIONS: Resection of CLM after a second-line chemotherapy regimen was found to be safe and was associated with a modest hope for definitive cure. This approach represents a viable option in patients with advanced CLM.
Authors: René Adam; Thomas Aloia; Francis Lévi; Dennis A Wicherts; Robbert J de Haas; Bernard Paule; Marie-Pierre Bralet; Mohamed Bouchahda; David Machover; Michel Ducreux; Vincent Castagne; Daniel Azoulay; Denis Castaing Journal: J Clin Oncol Date: 2007-10-10 Impact factor: 44.544
Authors: L F de Geus-Oei; H W M van Laarhoven; E P Visser; R Hermsen; B A van Hoorn; Y J L Kamm; P F M Krabbe; F H M Corstens; C J A Punt; W J G Oyen Journal: Ann Oncol Date: 2007-10-24 Impact factor: 32.976
Authors: Dario Ribero; Huamin Wang; Matteo Donadon; Daria Zorzi; Melanie B Thomas; Cathy Eng; David Z Chang; Steven A Curley; Eddie K Abdalla; Lee M Ellis; Jean-Nicolas Vauthey Journal: Cancer Date: 2007-12-15 Impact factor: 6.860
Authors: Dan G Blazer; Yoji Kishi; Dipen M Maru; Scott Kopetz; Yun Shin Chun; Michael J Overman; David Fogelman; Cathy Eng; David Z Chang; Huamin Wang; Daria Zorzi; Dario Ribero; Lee M Ellis; Katrina Y Glover; Robert A Wolff; Steven A Curley; Eddie K Abdalla; Jean-Nicolas Vauthey Journal: J Clin Oncol Date: 2008-10-20 Impact factor: 44.544
Authors: Robbert J de Haas; Dennis A Wicherts; Eduardo Flores; Daniel Azoulay; Denis Castaing; René Adam Journal: Ann Surg Date: 2008-10 Impact factor: 12.969
Authors: Matthew T Seymour; Timothy S Maughan; Jonathan A Ledermann; Clare Topham; Roger James; Stephen J Gwyther; David B Smith; Stephen Shepherd; Anthony Maraveyas; David R Ferry; Angela M Meade; Lindsay Thompson; Gareth O Griffiths; Mahesh Kb Parmar; Richard J Stephens Journal: Lancet Date: 2007-07-14 Impact factor: 79.321
Authors: Bernard Nordlinger; Halfdan Sorbye; Bengt Glimelius; Graeme J Poston; Peter M Schlag; Philippe Rougier; Wolf O Bechstein; John N Primrose; Euan T Walpole; Meg Finch-Jones; Daniel Jaeck; Darius Mirza; Rowan W Parks; Laurence Collette; Michel Praet; Ullrich Bethe; Eric Van Cutsem; Werner Scheithauer; Thomas Gruenberger Journal: Lancet Date: 2008-03-22 Impact factor: 79.321
Authors: Junichi Shindoh; Ching-Wei D Tzeng; Thomas A Aloia; Steven A Curley; Giuseppe Zimmitti; Steven H Wei; Steven Y Huang; Armeen Mahvash; Sanjay Gupta; Michael J Wallace; Jean-Nicolas Vauthey Journal: Ann Surg Oncol Date: 2013-02-03 Impact factor: 5.344
Authors: Axel Wein; Jürgen Siebler; Ruediger Goertz; Kerstin Wolff; Nicola Ostermeier; Dagmar Busse; Andreas E Kremer; Franz Koch; Alexander Hagel; Michael Farnbacher; Ferdinand J Kammerer; Markus F Neurath; Robert Gruetzmann Journal: Case Rep Oncol Date: 2016-07-09
Authors: Orlando Jorge Martins Torres; Márcio Carmona Marques; Fabio Nasser Santos; Igor Correia de Farias; Anelisa Kruschewsky Coutinho; Cássio Virgílio Cavalcante de Oliveira; Antonio Nocchi Kalil; Celso Abdon Lopes de Mello; Jaime Arthur Pirola Kruger; Gustavo Dos Santos Fernandes; Claudemiro Quireze; André M Murad; Milton José de Barros E Silva; Charles Edouard Zurstrassen; Helano Carioca Freitas; Marcelo Rocha Cruz; Rui Weschenfelder; Marcelo Moura Linhares; Leonaldson Dos Santos Castro; Charles Vollmer; Elijah Dixon; Héber Salvador de Castro Ribeiro; Felipe José Fernandez Coimbra Journal: Arq Bras Cir Dig Date: 2016 Jul-Sep